Tesa + Ipa Blend

This blend pairs two secretagogues that bind different pituitary receptors yet converge on the same outcome: a release of the body's own growth hormone.

What the research says about each component:

• Tesamorelin is a stabilized version of hypothalamic GHRH. It engages the GHRH receptor on somatotroph cells and has been an approved medicine in the US since 2010, tested in two phase 3 trials in HIV patients with excess abdominal fat.
• Ipamorelin was described in 1998 as the first selective GH secretagogue. It activates the ghrelin receptor GHS-R1a; in pigs it left ACTH, cortisol and prolactin untouched, which sets it apart from GHRP-2 and GHRP-6.
• When a GHRH signal and a ghrelin signal arrive together, the resulting GH pulse in studies is larger than either compound produces on its own. The pathways add up rather than compete.

Mechanistically the output stays pulsatile: the pituitary secretes GH in bursts and the IGF-1 feedback loop remains intact, which separates this approach from injected recombinant GH that bypasses pulsatility. Both peptides come lyophilized in one vial; the mixing ratio is part of the size shown on the page.

In studies the combination is regarded as well tolerated, but robust evidence exists only for the individual compounds, above all tesamorelin. Long-term observations of the blend itself are missing.

• Redness, a feeling of pressure or short-lived irritation at the injection site are the most frequent findings.
• Fluid retention and tingling or numbness in the hands (a carpal tunnel type pattern) accompany raised GH levels; the literature describes them as dose-dependent and reversible.
• Fasting glucose may rise and insulin sensitivity may dip for a while.
• Occasional grogginess or tiredness right after dosing has been reported, in line with the GH peak.

This summary is no substitute for medical advice.

• Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV - phase 3 data on tesamorelin in HIV patients with abdominal fat accumulation.
• Ipamorelin, the first selective growth hormone secretagogue - first description of selectivity without cortisol or prolactin rise in animals.
• The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats - twelve-week animal study of ipamorelin on bone.